2021 Deal-Making Snapshot
Bolt-On M&A Emphasis Continued In 2021, While Alliance Activity Increased
Executive Summary
M&A deals valued at $10bn or more were scarce in 2021, as the industry focused on easier-to-integrate bolt-ons. Alliance activity increased, but the average value on licensing and partnership deals was lower than in 2020.
You may also be interested in...
Concert’s CTP-543 Shows Advantages Over Lilly, Pfizer Candidates For Alopecia
Concert’s deuterated ruxolitinib analog is potentially third in line to market for alopecia areata, behind Lilly’s Olumiant and a Pfizer JAK3 inhibitor, but may be demonstrating a best-in-class profile.
Asia Deal Watch: Taiho Brings Cullinan Pearl Back In House
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
From Regulatory Affairs To R&D, Sanofi’s Mura Has Broad Strategic View
From a legal family in her native Brazil, Raquel Mura built on her passion for science to work in consumer health care, nutritionals and pharmaceuticals, rising to an R&D leadership position at Sanofi.